Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.
Chhabra, S., Chang, S.C., Nguyen, H.M., Huq, R., Tanner, M.R., Londono, L.M., Estrada, R., Dhawan, V., Chauhan, S., Upadhyay, S.K., Gindin, M., Hotez, P.J., Valenzuela, J.G., Mohanty, B., Swarbrick, J.D., Wulff, H., Iadonato, S.P., Gutman, G.A., Beeton, C., Pennington, M.W., Norton, R.S., Chandy, K.G.(2014) FASEB J 28: 3952-3964
- PubMed: 24891519 
- DOI: 10.1096/fj.14-251967
- Primary Citation of Related Structures:  
2MCR, 2MD0 - PubMed Abstract: 
The voltage-gated potassium (Kv) 1.3 channel is widely regarded as a therapeutic target for immunomodulation in autoimmune diseases. ShK-186, a selective inhibitor of Kv1.3 channels, ameliorates autoimmune diseases in rodent models, and human phase 1 trials of this agent in healthy volunteers have been completed ...